Immune-Onc Therapeutics

@ImmuneOnc

Dedicated to the discovery and development of novel biologic treatments for cancer patients

Vrijeme pridruživanja: kolovoz 2016.

Tweetovi

Blokirali ste korisnika/cu @ImmuneOnc

Jeste li sigurni da želite vidjeti te tweetove? Time nećete deblokirati korisnika/cu @ImmuneOnc

  1. 12. sij

    Panelists including CEO at conference ahead of agreed will be driver of innovation in over the next ten years.

    Poništi
  2. 12. sij

    Count-down to our panel on what's next in the oncology landscape. Don't miss it! Today at 1:45-2:15pm conference.

    Poništi
  3. 12. sij

    will join fellow CEOs to discuss new progress in . Our focus is on new therapies for . Join us today at 1:45-2:15pm conference.

    Poništi
  4. 12. sij

    Interested in what's next for ? If attending , stop by first and hear what our CEO and other biotech CEOs discuss. Sunday 1:45-2:15pm.

    Poništi
  5. 11. sij

    We're excited to take part in . See you there and have a great !

    Poništi
  6. 10. sij

    Heading to ? First, join us at . CEO will be part of a panel discussing developments in the landscape on Sunday, 1:45-2:15pm.

    Poništi
  7. , a company, adds industry vets to executive team and advisory boards: Dr. Paul Woodard appointed CMO, Dr. An Song promoted to CSO, Dr. Zhengbin (Bing) Yao joins Board of Directors and Dr. Greg Cosma appointed to SAB.

    Poništi
  8. ’s SVP of Development Sciences, An Song shared insights on a novel target for () at the Precision:Blood Cancer R&D Summit in SF.

    Poništi
  9. Tomorrow, ’s SVP of Development Sciences An Song will join leaders in cancer R&D as a featured speaker at the Precision:Blood Cancer R&D Summit in SF. Don’t miss her presentation on a novel target for (), 12:00pm, 9/17.

    Poništi
  10. CEO discusses the untapped potential of cell targeted therapies in

    Poništi
  11. Day 2 of the Stanford Drug Discovery Symposium is packed with leading edge research. Immune-Onc Therapeutics CEO looks forward to an engaging talk as part of the Discovery Showcase later this am.

    Poništi
  12. is excited to participate in the Stanford Drug Discovery Symposium . Congratulations to Lifetime Achievement awardee, John Martin, seen here with our CEO and SVP, Development Sciences, An Song.

    Poništi
  13. The research is the outcome of many years of collaboration between and the teams at and . We are grateful to Alec Zhang, Zhiqiang An and Ningyan Zhang and their teams for their dedication and continued partnership.

    Poništi
  14. aims to move novel research in () into first phase of clinical testing in 2019 based on research resulting from collaboration with and .

    Poništi
  15. names first target in its portfolio based on work published today in in collaboration with and researchers describing a novel target for () and a potential treatment approach.

    Poništi
  16. is pleased to share new non-clinical research published today in on a novel target and potential treatment approach for . The research is the outcome of many years of collaboration with the teams at .

    Poništi
  17. Poništi
  18. Poništi
  19. Immune-Onc is proud to appoint Dr. Adrian Jubb as Chief Medical Officer and Dr. An Song as SVP of Development Sciences. Welcome to the team!

    Poništi
  20. Poništi

Čini se da učitavanje traje već neko vrijeme.

Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.

    Možda bi vam se svidjelo i ovo:

    ·